Closing Timeline and Legal Heavyweights Behind the Deal
The acquisition is expected to close in the first half of 2026, pending standard regulatory approvals. Until then, both companies will operate independently.
Cravath, Swaine & Moore LLP led Illumina’s legal team, with partners Ting Chen and Daniel Cerqueira steering M&A, supported by top-tier counsel across tax, antitrust, IP, environmental, and executive compensation disciplines. Goldman Sachs & Co. LLC acted as Illumina’s financial adviser.
On the other side, Freshfields LLP and Richards, Layton & Finger PC advised Standard BioTools, with financial advice provided by Centerview Partners LLC, backed by legal guidance from Skadden, Arps, Slate, Meagher & Flom LLP.
